Objective:To investigate the clinical efficacy and prognosis of the treatment of dangerous placenta previa treated with cardoprost tromethamine and mifepristone. Methods:88 cases of pernicious placenta previa patients admitted to our hospital from September 2015 to September 2017 were randomly divided into two groups, 44 cases in each group.Patients in the two groups underwent cesarean section, and all patients were given conventional treatment of oxytocin and gauze strip, patients in control group were treated with mifepristone on this basis, patients in observation group were treated with pristinol three alcohol combined with mifepristone. Hemostatic effect, the hemodynamic index of 24 h after operation, the effect of maternal prognosis and the occurrence of adverse reactions in the two groups were compared. Results:2 h vaginal bleeding, intraoperative bleeding and postoperative 2-24 h vaginal bleeding volume ofthe observation group were significantly lower than those of the control group (P<0.01). Incidence of postpartum hemorrhage in the observation group was 9.09%, which was significantly lower than the 25.00% in the control group (P<0.01).Compared with the preoperative 24 h, the systolic blood pressure, diastolic blood pressure, and mean arterial pressure of the two groups decreased significantly after operation, and the heart rate increased significantly,however, the observation group changed less than the control group(P<0.05).The incidence of puerperal disease and disseminated intravascular coagulation in the observation group was 2.27% and 2.27%,compared with 15.91% and 13.64% in the control group, both were significantly decreased (P<0.01), in the observation group, there was no case of hysterectomy. The hysterectomy rate in the observation group was 0, which was equivalent to 2.27% in the control group(P>0.05), blood lochia duration in the observation group was (7.12±1.53) d, which was significantly shorter than that in the control group[(9.85±1.28) d, P<0.01]. The incidence of adverse reactions in the observation group was 18.18%, which was equivalent to 11.36% of the control group (P>0.05).Conclusion:Cataprost tromethamine combined with mifepristone is effective for the treatment of dangerous placenta previa, maternal postpartum hemorrhage is less, hemodynamic parameters are stable, maternal prognosis is good, adverse reactions are mild, and has clinical promotion value.